Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

A. Bulava, D. Wichterle, A. Mokráček, P. Osmančík, P. Budera, P. Kačer, L. Vetešková, P. Němec, T. Skála, P. Šantavý, J. Chovančík, P. Branny, V. Rizov, M. Kolesár, I. Šafaříková, M. Rybář, SURHYB Trial Investigators

. 2024 ; 26 (2) : . [pub] 20240201

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007258

Grantová podpora
NV19-02-00046 Ministry of Health of the Czech Republic

AIMS: Data on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS AND RESULTS: The trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation [Hybrid Group (HG)] or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalization for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the HG [41.1% vs. 67.4%, hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.26-0.57, P < 0.001] as well as the primary clinical endpoint (19.9% vs. 40.1%, HR = 0.51, 95% CI: 0.29-0.86, P = 0.012). The trial groups did not differ in all-cause mortality (10.6% vs. 8.6%, HR = 1.17, 95%CI: 0.51-2.71, P = 0.71). The major complications of catheter ablation were infrequent (1.9%). CONCLUSION: Pre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007258
003      
CZ-PrNML
005      
20240423155832.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae040 $2 doi
035    __
$a (PubMed)38306687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bulava, Alan $u Faculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia $1 https://orcid.org/000000021742207X
245    10
$a Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial / $c A. Bulava, D. Wichterle, A. Mokráček, P. Osmančík, P. Budera, P. Kačer, L. Vetešková, P. Němec, T. Skála, P. Šantavý, J. Chovančík, P. Branny, V. Rizov, M. Kolesár, I. Šafaříková, M. Rybář, SURHYB Trial Investigators
520    9_
$a AIMS: Data on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS AND RESULTS: The trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation [Hybrid Group (HG)] or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalization for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the HG [41.1% vs. 67.4%, hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.26-0.57, P < 0.001] as well as the primary clinical endpoint (19.9% vs. 40.1%, HR = 0.51, 95% CI: 0.29-0.86, P = 0.012). The trial groups did not differ in all-cause mortality (10.6% vs. 8.6%, HR = 1.17, 95%CI: 0.51-2.71, P = 0.71). The major complications of catheter ablation were infrequent (1.9%). CONCLUSION: Pre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x diagnóza $x chirurgie $x farmakoterapie $7 D001281
650    _2
$a výsledek terapie $7 D016896
650    12
$a supraventrikulární tachykardie $x chirurgie $7 D013617
650    _2
$a antiarytmika $x terapeutické užití $7 D000889
650    _2
$a krvácení $7 D006470
650    12
$a katetrizační ablace $x škodlivé účinky $x metody $7 D017115
650    _2
$a recidiva $7 D012008
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wichterle, Dan $u Cardiology Department, Institute for Clinical and Experimental Medicine, Prague, Czechia $1 https://orcid.org/0000000204485143 $7 xx0101417
700    1_
$a Mokráček, Aleš $u Faculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia
700    1_
$a Osmančík, Pavel $u Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czechia $1 https://orcid.org/0000000304824448 $7 xx0104796
700    1_
$a Budera, Petr $u Cardiology Department, Institute for Clinical and Experimental Medicine, Prague, Czechia $1 https://orcid.org/0000000155478704 $7 xx0270813
700    1_
$a Kačer, Petr $u Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czechia $1 https://orcid.org/0000000216625828
700    1_
$a Vetešková, Linda $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czechia
700    1_
$a Němec, Petr $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czechia $1 https://orcid.org/000000024542913X
700    1_
$a Skála, Tomáš $u Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czechia $1 https://orcid.org/0000000249435588
700    1_
$a Šantavý, Petr $u Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czechia $1 https://orcid.org/0000000268975344 $7 xx0211055
700    1_
$a Chovančík, Jan $u Cardilogy Department, Hospital Agel Třinec-Podlesí, Třinec, Czechia
700    1_
$a Branny, Piotr $u Cardilogy Department, Hospital Agel Třinec-Podlesí, Třinec, Czechia $1 https://orcid.org/0009000394716850
700    1_
$a Rizov, Vitalii $u Cardilogy Department, Masaryk Hospital, Ústí nad Labem, Czechia $1 https://orcid.org/0009000466034315
700    1_
$a Kolesár, Miroslav $u Cardilogy Department, Masaryk Hospital, Ústí nad Labem, Czechia $1 https://orcid.org/0009000862479850
700    1_
$a Šafaříková, Iva $u Faculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia $1 https://orcid.org/0000000167763561 $7 xx0229301
700    1_
$a Rybář, Marian $u Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czechia
710    2_
$a SURHYB Trial Investigators
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 26, č. 2 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38306687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155829 $b ABA008
999    __
$a ok $b bmc $g 2081318 $s 1217025
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 2 $e 20240201 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$a NV19-02-00046 $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace